Noble Financial Has Pessimistic View of UNCY Q2 Earnings

Key Points

• Noble Financial cut its Q2 2027 EPS estimate for Unicycive Therapeutics to $0.75 from $0.91, while projecting $1.06 for Q3 and $1.24 for Q4. The current full-year consensus estimate remains a loss of $1.49 per share.
• Unicycive reported a quarterly loss of $0.06 per share, beating the consensus estimate of a $0.47 loss. However, analyst sentiment is mixed, with the stock holding an average “Hold” rating and an average price target of $18.25.
• UNCY shares opened at $5.40, with a market capitalization of about $147.9 million and a 52-week range of $3.71 to $8.74. Institutional investors own approximately 40.42% of the company.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Noble Financial reduced their Q2 2027 earnings per share estimates for shares of Unicycive Therapeutics in a report released on Thursday, August 13th. Noble Financial analyst R. Leboyer now anticipates that the company will earn $0.75 per share for the quarter, down from their previous estimate of $0.91. The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($1.49) per share. Noble Financial also issued estimates for Unicycive Therapeutics' Q3 2027 earnings at $1.06 EPS and Q4 2027 earnings at $1.24 EPS.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.41.

A number of other research analysts also recently commented on the company. Benchmark lowered their price objective on Unicycive Therapeutics from $18.00 to $13.00 and set a "speculative buy" rating for the company in a research note on Wednesday, July 1st. Zacks Research cut shares of Unicycive Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, July 21st. Wall Street Zen lowered Unicycive Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 27th. Weiss Ratings upgraded Unicycive Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, June 9th. Finally, HC Wainwright reduced their price objective on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a "buy" rating for the company in a report on Tuesday, June 30th. Five equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Unicycive Therapeutics currently has an average rating of "Hold" and an average target price of $18.25.

Unicycive Therapeutics Stock Up 0.2%

Shares of UNCY stock opened at $5.40 on Friday. The company has a market cap of $147.91 million, a P/E ratio of -3.09 and a beta of 1.79. The business has a 50 day moving average of $5.97 and a two-hundred day moving average of $6.65. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $8.74.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company's stock valued at $104,000 after acquiring an additional 21,525 shares during the period. Lazard Asset Management LLC purchased a new position in Unicycive Therapeutics during the 2nd quarter worth approximately $55,000. Vanguard Group Inc. raised its stake in Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company's stock valued at $2,873,000 after purchasing an additional 52,925 shares during the period. Squarepoint Ops LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at $512,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Unicycive Therapeutics in the third quarter valued at $182,000. Hedge funds and other institutional investors own 40.42% of the company's stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source